{"schema_version":"secwatch.filing_event.v1","accession":"0001576280-23-000019","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.669866+00:00","generated_at":"2026-06-19T02:40:19.040361+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Guardant Health Q4 revenue $126.9M (+17% YoY); net loss widens to $139.9M; guides FY23 rev $525-540M","bullets":["Q4 revenue $126.9M (+17% YoY); full-year revenue $449.5M (+20% YoY).","Q4 clinical test volume 36,000 (+41% YoY); biopharma 8,200 (+24% YoY).","Q4 net loss $139.9M ($1.36/share) vs $90.9M ($0.89) prior year; non-GAAP net loss $119.6M.","FY23 revenue guidance $525-540M (17-20% growth); expects free cash outflow ~$350M.","ECLIPSE study for Shield CRC screening showed 83% sensitivity, 90% specificity; FDA approved Guardant360 CDx for breast cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001576280-23-000019","json":"https://secwatch.observer/filing/0001576280-23-000019.json","markdown":"https://secwatch.observer/filing/0001576280-23-000019.md","text":"https://secwatch.observer/filing/0001576280-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000019/0001576280-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000019/gh-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:40:19.040361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cb70ad5d48f39f21435b8479da0ca5843b55d0a","claim":"Guardant Health, Inc. reported the year ended December 31, 2022 results: revenue $449.5 million, net income $654.6 million, EPS $6.41 per share.","evidence_excerpt":"customers in the fourth quarter of 2022, representing an increase of 41% and 24%, respectively, over the fourth quarter of 2021. Full Year 2022 Financial Highlights • Revenue of $449.5 million for the full year 2022, an increase of 20% over the full year 2021. • Reported 124,800 tests to clinical customers and 26,000 tests to biopharmaceutical customers in the full","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000019/0001576280-23-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$449.5 million"},{"label":"Net income","value":"$654.6 million"},{"label":"EPS","value":"$6.41 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9d20fc4459eb1108a283f7dfb06ec6ce16499b0d","claim":"Guardant Health, Inc. reported the three months ended December 31, 2022 results: revenue $126.9 million, net income $139.9 million, EPS $1.36 per share.","evidence_excerpt":"data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights • Revenue of $126.9 million for the fourth quarter of 2022, an increase of 17% over the fourth quarter of 2021. • Reported 36,000 tests to clinical customers and 8,200 tests to biopharmaceutical customers","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000019/0001576280-23-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$126.9 million"},{"label":"Net income","value":"$139.9 million"},{"label":"EPS","value":"$1.36 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}